mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma

Area of Science:

• Cellular Biology
• Cancer Research
• Epigenetics

Background:

• SWI/SNF chromatin remodeling complexes are crucial for gene regulation and are implicated in cancer.
• ARID1A-containing SWI/SNF is a tumor suppressor in hepatocellular carcinoma (HCC), but its regulation by oncogenic signals is unclear.
• The mechanistic target of rapamycin (mTOR) pathway is a central regulator of cell growth and a driver of HCC.

Purpose of the Study:

• To investigate the regulatory relationship between mTOR signaling and the ARID1A-SWI/SNF complex in HCC.
• To elucidate the role of the mTOR-ARID1A axis in liver cancer development and therapeutic response.

Main Methods:

• Co-immunoprecipitation assays to detect protein interactions.
• Western blotting and proteasomal degradation assays to assess protein stability.
• In vitro cell culture and in vivo mouse models to evaluate tumor growth.
• Analysis of patient tumor data for mutually exclusive mutations.

Main Results:

• mTOR complex 1 (mTORC1) directly interacts with ARID1A, promoting its ubiquitination and proteasomal degradation.
• The mTORC1-ARID1A interaction enhances oncogenic chromatin remodeling and YAP-dependent transcription, promoting HCC cell growth and tumor development.
• Dysregulation of the mTORC1-ARID1A axis leads to resistance to mTOR-targeted therapies.
• Mutations in mTOR and SWI/SNF components are mutually exclusive in HCC, suggesting a shared functional role.

Conclusions:

• The ARID1A-SWI/SNF complex is a novel regulatory target of oncogenic mTOR signaling in HCC.
• The mTORC1-ARID1A axis is a critical pathway in mTORC1-driven hepatocarcinogenesis.
• Targeting this axis holds potential for therapeutic interventions in HCC, particularly in combination with mTOR- and YAP-targeted therapies.